Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNEVKA)

Drug Name
E2012 Drug Info
Synonyms
870843-42-8; E 2012; (E)-1-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-3-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE]PIPERIDIN-2-ONE; E-2012; UNII-3LSD4Y5F0F; 3LSD4Y5F0F; CHEMBL1224151; J-501810; (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]piperidin-2-one; (e)-1-((1s)-1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene)piperidin-2-one; PUOAETJYKQITMO-LANLRWRYSA-N
Cross-matching ID
PubChem CID
11560787
ChEBI ID
CHEMBL1224151
CAS Number
CAS 870843-42-8
TTD Drug ID
D0F0JJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.22 0.00e+0 48/60 (80%) MT1E;MT1M;MT1F;...
Retinol metabolism 2.08 0.00e+0 41/68 (60.29%) UGT2B15;UGT2B28;ALDH1A2;...
Oxidative phosphorylation 2.07 0.00e+0 93/133 (69.92%) NDUFB2;COX7C;COX6C;...
Fat digestion and absorption 1.98 0.00e+0 35/43 (81.4%) PLA2G2A;FABP1;ACAT1;...
Fatty acid degradation 1.91 1.67e-3 40/43 (93.02%) ACSBG1;ACAT1;ADH1C;...
Cardiac muscle contraction 1.78 2.93e-2 64/87 (73.56%) ATP1A2;COX7C;COX6C;...
Porphyrin and chlorophyll metabolism 1.78 2.63e-2 23/43 (53.49%) UGT2B15;UGT2B28;HEPH;...
Caffeine metabolism 1.75 3.35e-2 5/6 (83.33%) NAT1;NAT2;CYP2A6
Linoleic acid metabolism 1.73 4.09e-2 21/29 (72.41%) PLAAT3;PLA2G2A;CYP2C9;...
Parkinson disease 1.72 3.68e-2 176/249 (70.68%) NDUFB2;COX7C;COX6C;...
Central carbon metabolism in cancer -1.62 4.23e-2 67/70 (95.71%) SLC1A5;MET;MAPK3;...
Osteoclast differentiation -1.63 4.05e-2 117/127 (92.13%) SIRPA;AKT1;IFNB1;...
Type II diabetes mellitus -1.65 3.77e-2 42/46 (91.3%) HK1;HK3;PIK3CA;...
Steroid biosynthesis -1.67 3.34e-2 19/20 (95%) CYP24A1;DHCR24;CYP51A1;...
Influenza A -1.67 3.19e-2 156/172 (90.7%) CPSF4;RAB11B;AKT1;...
Notch signaling pathway -1.70 2.85e-2 49/59 (83.05%) HES1;DVL2;APH1A;...
Natural killer cell mediated cytotoxicity -1.70 2.77e-2 99/131 (75.57%) IFNA17;PTK2B;MAPK3;...
Fc epsilon RI signaling pathway -1.72 2.26e-2 57/68 (83.82%) PLA2G4C;IL3;MAPK1;...
Toll-like receptor signaling pathway -1.72 2.31e-2 94/104 (90.38%) AKT1;IFNB1;TOLLIP;...
Toxoplasmosis -1.72 2.43e-2 103/112 (91.96%) ITGB1;LAMA5;LAMB2;...
Inflammatory bowel disease -1.73 2.44e-2 58/65 (89.23%) HLA-DOA;IL13;HLA-DPA1;...
Herpes simplex virus 1 infection -1.74 2.25e-2 165/498 (33.13%) TAPBP;TYK2;PML;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 1.97e-2 79/89 (88.76%) RAF1;ALK;NFKB1;...
Systemic lupus erythematosus -1.75 2.10e-2 45/135 (33.33%) CD40;CD80;CD86;...
Autoimmune thyroid disease -1.78 1.70e-2 46/53 (86.79%) CD40;CD80;HLA-F;...
B cell receptor signaling pathway -1.79 1.74e-2 71/81 (87.65%) MAPK1;RAC2;RAF1;...
Staphylococcus aureus infection -1.84 1.16e-2 72/95 (75.79%) KRT24;HLA-DMB;FCGR2A;...
Hematopoietic cell lineage -1.85 8.68e-3 90/99 (90.91%) HLA-DOA;HLA-DPA1;CSF1;...
Leishmaniasis -1.85 9.47e-3 67/77 (87.01%) HLA-DMB;FCGR2A;STAT1;...
Antigen processing and presentation -1.86 9.26e-3 60/78 (76.92%) NFYC;TAPBP;KLRC3;...
Phagosome -1.87 7.72e-3 118/152 (77.63%) HLA-F;DYNC2H1;HLA-C;...
Tuberculosis -1.89 5.79e-3 159/180 (88.33%) MAPK14;HLA-DOA;MAPK13;...
Neutrophil extracellular trap formation -1.90 6.61e-3 101/189 (53.44%) FCGR2A;HMGB1;PIK3CA;...
Synaptic vesicle cycle -1.95 5.79e-3 63/78 (80.77%) SLC6A2;AP2A2;ATP6V0C;...
Th1 and Th2 cell differentiation -1.99 4.63e-3 80/92 (86.96%) JAK1;CHUK;ZAP70;...
Allograft rejection -2.20 0.00e+0 32/38 (84.21%) CD40;CD80;HLA-F;...
Type I diabetes mellitus -2.20 0.00e+0 38/43 (88.37%) PTPRN2;CD80;HLA-F;...
Graft-versus-host disease -2.26 0.00e+0 32/42 (76.19%) KLRD1;CD80;HLA-F;...
Asthma -2.33 0.00e+0 25/31 (80.65%) IL9;CD40;HLA-DOA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H